Vaccine for Birth Defects Didn’t Work Well, Won’t Be Continued: Moderna

The vaccine targeted a virus linked to birth defects.

A sign marks the headquarters of vaccine maker Moderna in Cambridge, Mass., on April 28, 2022. Brian Snyder/Reuters

Moderna on Oct. 22 said its vaccine for cytomegalovirus (CMV) did not perform well in a clinical trial.

The investigational shot did not meet the primary efficacy endpoint in preventing CMV infection in healthy females of childbearing age, or aged 16 to 40, Moderna said.